Health Care • Medical Specialities
$41.25 ▲ +0.66
(+1.63%)
MKT CAP: $5.26B • VOL: 1.41M
52W L $19 52W H $42
CON // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $2.16B | $1.90B | $1.84B |
| YoY Revenue Growth % | +13.9% | +3.4% | — |
| Gross Profit | $951.9M | $836.1M | $808.8M |
| Gross Margin % | 44.0% | 44.0% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $334.0M | $304.8M | $287.6M |
| Operating Margin % | 15.4% | 16.0% | 15.6% |
| Net Income (GAAP) | $166.4M | $166.5M | $179.9M |
| EBITDA (Normalized) | $399.9M | $356.2M | $353.8M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $279.4M | $274.7M | $234.3M |
| Capital Expenditures (CapEx) | $82.3M | $64.3M | $82.7M |
| Free Cash Flow (FCF) | $197.1M | $210.3M | $151.6M |
| FCF Margin % | 9.1% | 11.1% | 8.2% |
| Return on Invested Capital (ROIC %) | 18.7% | 22.0% | 13.0% |
| Cash & Short-Term Equivalents | $79.9M | $183.3M | $318.2M |
| Total Debt (Short + Long Term) | $1.10B | $1.00B | $677.0M |
| Total Stockholders' Equity | $393.3M | $275.7M | $1.39B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CON.